Open Molecular Software Foundation’s OpenFold Consortium Launches Research Fellowship at the University of Washington’s Institute for Protein Design

Open Molecular Software Foundation’s OpenFold Consortium Launches Research Fellowship at the University of Washington’s Institute for Protein Design




Open Molecular Software Foundation’s OpenFold Consortium Launches Research Fellowship at the University of Washington’s Institute for Protein Design

BERKELEY, Calif.–(BUSINESS WIRE)–The Open Molecular Software Foundation (OMSF) today announced a new research fellowship between the OpenFold Consortium and the University of Washington Institute for Protein Design (IPD). Nobel Laureate David Baker is the Director of the IPD, a professor of biochemistry, and HHMI Investigator at UW Medicine. This fellowship is aimed at accelerating the development of open-source artificial intelligence tools for protein structure prediction and design ultimately to be used for new drug discovery.


The fellowship will support graduate students and postdoctoral scholars in the Baker Lab. With funding from the OpenFold Consortium fellows will focus on creating new state-of-the-art AI models for antibody-antigen design and structure prediction. Following an approach shared by OpenFold and the IPD, all resulting code from this collaboration will be released under permissive licenses for use by researchers and companies worldwide.

“The AI revolution in biology is built on a foundation of openness — researchers sharing data, code, and ideas freely so that others can build on them,” said Baker. “We’re excited to continue this tradition with OpenFold.”

“This collaboration with the Baker Lab marks a defining moment for open biomolecular AI,” said Dr. Woody Sherman, Chair of the OpenFold Consortium Executive Committee and Chief Innovation Officer at PsiThera. “This collaboration brings extraordinary depth across protein design, structure prediction, and large-scale experimental data generation. By building these capabilities as open, shared infrastructure, OpenFold is laying the foundation for a new era of biological discovery where AI models become community resources that accelerate innovation, enable entirely new classes of therapeutics, and deliver impact far beyond what any single organization could achieve.”

As part of this collaboration, the Baker Lab will conduct AI model development. To enhance the longevity and ease-of-use of new software, OpenFold engineers will provide technical support for packaging, documentation, and maintenance. All finished models developed with OMSF fellowship support will be shared publicly under permissive licenses.

About OMSF and OpenFold

The Open Molecular Software Foundation is a nonprofit 501(c)(3) organization supporting open, community-driven molecular software. The OpenFold project within OMSF advances open biomolecular AI by enabling shared infrastructure, evaluation, and community resources to accelerate scientific progress. OMSF is modeled after open source consortia in software technology such as the Linux Foundation.

The OpenFold Consortium is supported by a growing community of academic, industry, and philanthropic partners committed to building open scientific infrastructure for the next era of biology. OpenFold welcomes mission-aligned supporters interested in accelerating open innovation in biomolecular AI and drug discovery.

About the UW Institute for Protein Design

The Institute for Protein Design at the University of Washington creates new molecules that solve challenges in medicine, technology, and sustainability. Founded in 2012 by Nobel laureate David Baker, the Institute unites and trains experts in AI, biochemistry, medicine, and other disciplines. The IPD is building proteins to improve health, prevent pandemics, eliminate pollution, and organize matter at the atomic scale.

Contacts

Media Contact:

Mallory R. Tollefson, Ph. D.

Business Development and Project Manager

mallory.tollefson@omsf.io
https://openfold.io/

LiveWorld Reports 2025 Financial Results

LiveWorld Reports 2025 Financial Results




LiveWorld Reports 2025 Financial Results

LiveWorld continues to increase its AI investment

CAMPBELL, Calif. and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) — LiveWorld, Inc. (OTC Markets: LVWD), today announced financial results for the year 2025.

Twelve Months 2025 Financial and Business Highlights

  • Total twelve-month revenues of $11.1 million
  • Healthcare revenues of $10 million in 2025
  • Net income from operations of $326,000
  • Net Cash of $5.7 million

Management Commentary

“We saw our 2025 revenues drop slightly when we compare to our 2024 revenues as our clients delt with the volatility and uncertainty of the current economy,” remarked David Houston, Chief Financial Officer, of LiveWorld. “While our revenues were down approximately 2% year-over-year we did improve our net income for the same period by over 376%. As we move into 2026, we will continue our investment in AI which will have an impact on the profits of the company. Finally, our clients have begun to expand their budgets with us again. Based on current bookings and forecasts we are cautiously optimistic our total revenues for 2026 will exceed our totals for 2025.”

“We have expanded our investment in AI products, announced our AI strategy and are steadily launching new AI based solutions,” said Peter Friedman, LiveWorld Chairman and CEO. “ Initial client response is positive and we expect these products to be the basis for revenue growth in the years to come.”

Financial Review for the twelve Months Ended December 31, 2025

Total revenues for the twelve months ended December 31, 2025 were approximately $11.1 million, as compared to approximately $11.3 million for the twelve months ended December 31, 2024. This was a decrease of approximately $208,000 or 2% period-over-period.

The company reported a net income for the twelve months of approximately $326,000 or 3% of total revenues. This compares to net income of approximately $69,000 or 1% of total revenues reported for the twelve months of 2024. This was an increase of approximately 376% when comparing the two periods.

The company finished the year with approximately $7.3 million in cash and cash equivalents, compared to approximately $6.6 million at the end of 2024. The net cash available for operations was approximately $5.7 million at the end of December 31, 2025, compared to the $6.2 million at the end of 2024. The company defines net cash available for operations as cash, less media expenditure commitments.

Detailed financial information may be downloaded at www.liveworld.com/ir or at https://www.otcmarkets.com/stock/LVWD/overview.

About LiveWorld

LiveWorld is a Human-Led, AI-Powered digital marketing agency and software company.  We unlock the full potential of social and digital media to transform customer relationships through integrated compliance, engagement, and insight solutions. 

Purpose-built for highly regulated healthcare and pharma brands, LiveWorld combines proactive compliance, expert-led social media moderation, dynamic community engagement, and AI-powered insights to help brands listen smarter, engage more meaningfully, and act with confidence. Our approach blends human expertise with advanced AI to deliver genuine human connections, ensure accuracy, safety, and relevance, turning real-world conversations into trusted intelligence and measurable business impact. 

LiveWorld clients include the number one brands in pharmaceuticals, healthcare, and financial-travel services. LiveWorld is headquartered in Campbell, California, with an additional office in New York City. Learn more at www.liveworld.com and @LiveWorld. 

“Safe Harbor” Statement Under The Private Securities Litigation Reform Act
This press release may contain forward-looking information concerning LiveWorld plans, objectives, future expectations, forecasts and prospects. These statements may include those regarding LiveWorld’s current or future financial performance including but not limited to lists of clients, revenue and profit, use of cash, investments, relationships and the actual or potential impact of stock option expense, and the results of its product development efforts. Actual results may differ materially from those expressed in the forward- looking statements made as a result of, among other things, final accounting adjustments and results, LiveWorld’s ability to attract new clients and preserve or expand its relationship with existing clients, LiveWorld’s ability to retain and attract high quality employees, including its management staff, the ability to deliver new innovative products in a timely manner, changing accounting treatments, and other risks applicable to the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to update these forward-looking statements to reflect subsequent events or circumstances.

LiveWorld Contacts
IR Contact:
David Houston
LiveWorld
dhouston@liveworld.com
(408) 615-8496

PR Contact:
Matthew Hammer
LiveWorld
mhammer@liveworld.com
(737) 212-9739

LIVEWORLD, INC.
UNAUDITED CONDENSED BALANCE SHEETS
(In thousands, except share data)
       
  December 31,   December 31,
    2025       2024  
ASSETS      
Current assets      
Cash and cash equivalent $ 7,313     $ 6,603  
Accounts receivable, net   1,309       682  
Prepaid expenses   246       290  
Total current assets   8,868       7,575  
       
Property and equipment, net   18       33  
Other assets   27       27  
Total assets $ 8,913     $ 7,635  
LIABILITIES AND STOCKHOLDERS’ EQUITY      
Current liabilities      
Accounts payable $ 242     $ 182  
Accrued employee expenses   595       1,068  
Other accrued liabilities   1,555       413  
Deferred revenue   761       860  
Total current liabilities   3,153       2,523  
Total liabilities   3,153       2,523  
       
Stockholders’ equity      
  Common stock: $0.001 par value, 100,000,000 shares authorized
45,633,442 issued and outstanding as of December 31, 2025, and
December 31, 2024, respectively
  34       34  
Additional paid-in capital   144,773       144,451  
Accumulated deficit   (139,047 )     (139,373 )
Total stockholders’ equity   5,760       5,112  
Total liabilities and stockholders’ equity $ 8,913     $ 7,635  
               

LIVEWORLD, INC.
CONDENSED STATEMENT OF OPERATIONS
(In thousands, except per share data)
       
  Twelve Months Ended
December 31,
    2025     2024
Total revenues $ 11,140   $ 11,348
Cost of revenues                  5,404                 6,023
Gross Margin                  5,736                 5,325
Operating Expense      
Product development                  1,336               1,048
Sales and marketing                  1,630               1,554
General and administrative                  2,504     2,634
Total operating expense                  5,470     5,236
Income from operations                     266     89
Income before tax                     266     89
Other Income                       88     5
Provision for income taxes                       28     25
Net income from operations                     326     69
       
Earnings per share analysis from operations:      
Basic income per share $ 0.01   $ 0.00
Shares used in computing basic loss per share   45,633,442     45,633,442
Diluted net income (loss) per share $ 0.01   $ 0.00
Shares used in computing diluted income (loss) per share   54,992,049     56,350,862
       
       
Departmental allocation of stock-based compensation:      
Cost of revenues $ 81   $ 80
Product development   21     18
Sales and marketing   31     33
General and administrative   188     189
Total stock-based compensation $ 321   $ 320
           

LIVEWORLD, INC.
CONDENSED STATEMENTS OF CASH FLOWS
(In thousands)
  Twelve Months Ended
December 31,
    2025       2024  
Cash flows from operating activities:      
Net income (loss) $ 326     $ 69  
Adjustments to reconcile net income (loss) provided by (used in) operating activities:    
Depreciation of long-lived assets   21       26  
Stock-based compensation   321       320  
Changes in operating assets and liabilities:      
Accounts receivable   (627 )     1,019  
Other assets   47       (66 )
Accounts payable   60       (56 )
Accrued liabilities   668       249  
Deferred revenue   (100 )     422  
Net cash provided by (used in) operating activities   716       1,983  
Cash flows from investing activities:      
Purchase of property and equipment   (6 )     (15 )
Net cash provided by (used in) investing activities   (6 )     (15 )
Cash flows from financing activities:      
Proceeds from exercise of stock options   —–       —-  
Net cash provided by (used for) financing activities   —–       —-  
Change in cash and cash equivalent   710       1,968  
Cash and cash equivalents, beginning of period   6,603       4,635  
Cash and cash equivalents, end of period $ 7,313     $ 6,603  
       
Supplemental disclosure of non-cash financing and investing activities:    
Income tax paid $ 28     $ 25  

LiveWorld Reports 2025 Financial Results

LiveWorld Reports 2025 Financial Results




LiveWorld Reports 2025 Financial Results

LiveWorld continues to increase its AI investment

CAMPBELL, Calif. and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) — LiveWorld, Inc. (OTC Markets: LVWD), today announced financial results for the year 2025.

Twelve Months 2025 Financial and Business Highlights

  • Total twelve-month revenues of $11.1 million
  • Healthcare revenues of $10 million in 2025
  • Net income from operations of $326,000
  • Net Cash of $5.7 million

Management Commentary

“We saw our 2025 revenues drop slightly when we compare to our 2024 revenues as our clients delt with the volatility and uncertainty of the current economy,” remarked David Houston, Chief Financial Officer, of LiveWorld. “While our revenues were down approximately 2% year-over-year we did improve our net income for the same period by over 376%. As we move into 2026, we will continue our investment in AI which will have an impact on the profits of the company. Finally, our clients have begun to expand their budgets with us again. Based on current bookings and forecasts we are cautiously optimistic our total revenues for 2026 will exceed our totals for 2025.”

“We have expanded our investment in AI products, announced our AI strategy and are steadily launching new AI based solutions,” said Peter Friedman, LiveWorld Chairman and CEO. “ Initial client response is positive and we expect these products to be the basis for revenue growth in the years to come.”

Financial Review for the twelve Months Ended December 31, 2025

Total revenues for the twelve months ended December 31, 2025 were approximately $11.1 million, as compared to approximately $11.3 million for the twelve months ended December 31, 2024. This was a decrease of approximately $208,000 or 2% period-over-period.

The company reported a net income for the twelve months of approximately $326,000 or 3% of total revenues. This compares to net income of approximately $69,000 or 1% of total revenues reported for the twelve months of 2024. This was an increase of approximately 376% when comparing the two periods.

The company finished the year with approximately $7.3 million in cash and cash equivalents, compared to approximately $6.6 million at the end of 2024. The net cash available for operations was approximately $5.7 million at the end of December 31, 2025, compared to the $6.2 million at the end of 2024. The company defines net cash available for operations as cash, less media expenditure commitments.

Detailed financial information may be downloaded at www.liveworld.com/ir or at https://www.otcmarkets.com/stock/LVWD/overview.

About LiveWorld

LiveWorld is a Human-Led, AI-Powered digital marketing agency and software company.  We unlock the full potential of social and digital media to transform customer relationships through integrated compliance, engagement, and insight solutions. 

Purpose-built for highly regulated healthcare and pharma brands, LiveWorld combines proactive compliance, expert-led social media moderation, dynamic community engagement, and AI-powered insights to help brands listen smarter, engage more meaningfully, and act with confidence. Our approach blends human expertise with advanced AI to deliver genuine human connections, ensure accuracy, safety, and relevance, turning real-world conversations into trusted intelligence and measurable business impact. 

LiveWorld clients include the number one brands in pharmaceuticals, healthcare, and financial-travel services. LiveWorld is headquartered in Campbell, California, with an additional office in New York City. Learn more at www.liveworld.com and @LiveWorld. 

“Safe Harbor” Statement Under The Private Securities Litigation Reform Act
This press release may contain forward-looking information concerning LiveWorld plans, objectives, future expectations, forecasts and prospects. These statements may include those regarding LiveWorld’s current or future financial performance including but not limited to lists of clients, revenue and profit, use of cash, investments, relationships and the actual or potential impact of stock option expense, and the results of its product development efforts. Actual results may differ materially from those expressed in the forward- looking statements made as a result of, among other things, final accounting adjustments and results, LiveWorld’s ability to attract new clients and preserve or expand its relationship with existing clients, LiveWorld’s ability to retain and attract high quality employees, including its management staff, the ability to deliver new innovative products in a timely manner, changing accounting treatments, and other risks applicable to the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to update these forward-looking statements to reflect subsequent events or circumstances.

LiveWorld Contacts
IR Contact:
David Houston
LiveWorld
dhouston@liveworld.com
(408) 615-8496

PR Contact:
Matthew Hammer
LiveWorld
mhammer@liveworld.com
(737) 212-9739

LIVEWORLD, INC.
UNAUDITED CONDENSED BALANCE SHEETS
(In thousands, except share data)
       
  December 31,   December 31,
    2025       2024  
ASSETS      
Current assets      
Cash and cash equivalent $ 7,313     $ 6,603  
Accounts receivable, net   1,309       682  
Prepaid expenses   246       290  
Total current assets   8,868       7,575  
       
Property and equipment, net   18       33  
Other assets   27       27  
Total assets $ 8,913     $ 7,635  
LIABILITIES AND STOCKHOLDERS’ EQUITY      
Current liabilities      
Accounts payable $ 242     $ 182  
Accrued employee expenses   595       1,068  
Other accrued liabilities   1,555       413  
Deferred revenue   761       860  
Total current liabilities   3,153       2,523  
Total liabilities   3,153       2,523  
       
Stockholders’ equity      
  Common stock: $0.001 par value, 100,000,000 shares authorized
45,633,442 issued and outstanding as of December 31, 2025, and
December 31, 2024, respectively
  34       34  
Additional paid-in capital   144,773       144,451  
Accumulated deficit   (139,047 )     (139,373 )
Total stockholders’ equity   5,760       5,112  
Total liabilities and stockholders’ equity $ 8,913     $ 7,635  
               

LIVEWORLD, INC.
CONDENSED STATEMENT OF OPERATIONS
(In thousands, except per share data)
       
  Twelve Months Ended
December 31,
    2025     2024
Total revenues $ 11,140   $ 11,348
Cost of revenues                  5,404                 6,023
Gross Margin                  5,736                 5,325
Operating Expense      
Product development                  1,336               1,048
Sales and marketing                  1,630               1,554
General and administrative                  2,504     2,634
Total operating expense                  5,470     5,236
Income from operations                     266     89
Income before tax                     266     89
Other Income                       88     5
Provision for income taxes                       28     25
Net income from operations                     326     69
       
Earnings per share analysis from operations:      
Basic income per share $ 0.01   $ 0.00
Shares used in computing basic loss per share   45,633,442     45,633,442
Diluted net income (loss) per share $ 0.01   $ 0.00
Shares used in computing diluted income (loss) per share   54,992,049     56,350,862
       
       
Departmental allocation of stock-based compensation:      
Cost of revenues $ 81   $ 80
Product development   21     18
Sales and marketing   31     33
General and administrative   188     189
Total stock-based compensation $ 321   $ 320
           

LIVEWORLD, INC.
CONDENSED STATEMENTS OF CASH FLOWS
(In thousands)
  Twelve Months Ended
December 31,
    2025       2024  
Cash flows from operating activities:      
Net income (loss) $ 326     $ 69  
Adjustments to reconcile net income (loss) provided by (used in) operating activities:    
Depreciation of long-lived assets   21       26  
Stock-based compensation   321       320  
Changes in operating assets and liabilities:      
Accounts receivable   (627 )     1,019  
Other assets   47       (66 )
Accounts payable   60       (56 )
Accrued liabilities   668       249  
Deferred revenue   (100 )     422  
Net cash provided by (used in) operating activities   716       1,983  
Cash flows from investing activities:      
Purchase of property and equipment   (6 )     (15 )
Net cash provided by (used in) investing activities   (6 )     (15 )
Cash flows from financing activities:      
Proceeds from exercise of stock options   —–       —-  
Net cash provided by (used for) financing activities   —–       —-  
Change in cash and cash equivalent   710       1,968  
Cash and cash equivalents, beginning of period   6,603       4,635  
Cash and cash equivalents, end of period $ 7,313     $ 6,603  
       
Supplemental disclosure of non-cash financing and investing activities:    
Income tax paid $ 28     $ 25  

Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors

Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors




Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors

ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) — Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the appointment of Kenneth D. Eichenbaum, M.D., M.S.E., to its Board of Directors. Dr. Eichenbaum is a board-certified anesthesiologist with clinical affiliations at Corewell Health William Beaumont University Hospital and Trinity Health Oakland Hospital, bringing deep clinical expertise and strategic insight developed through more than 20 years of evaluating biotechnology and medical device companies and advising investment firms. He completed a fellowship at Stanford University Medical Center and earned his M.D. from the Icahn School of Medicine at Mount Sinai, with additional degrees in engineering from the University of Pennsylvania and in finance from The Wharton School.

“As we continue advancing innovative solutions in women’s health, Dr. Eichenbaum brings a unique combination of clinical and technical expertise, along with deep financial insight, that will be invaluable to Femasys,” said Kathy Lee-Sepsick, Founder and Chief Executive Officer of Femasys. “His experience evaluating and advising biotechnology and medical device companies adds an important strategic perspective to our Board, and we are thrilled to welcome him at this important stage in the Company’s growth.”

Dr. Eichenbaum commented, “Femasys is advancing innovative, non-surgical solutions designed to improve the patient experience while reducing cost and complexity in women’s reproductive care. I look forward to working with the Board and management team to support the Company’s continued growth and innovation.”

The Company also expresses its appreciation to Joshua Silverman for his service on the Board of Directors. His capital markets perspective and strategic counsel supported Femasys during a period of important growth and development.

About Femasys
Femasys is a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide through its broad, patent-protected portfolio of novel, in-office therapeutic and diagnostic products. As a U.S. manufacturer with global regulatory approvals, Femasys is actively commercializing its lead product innovations in the U.S. and key international markets. Femasys’ fertility portfolio includes FemaSeed® Intratubal Insemination (ITI), a groundbreaking first-step infertility treatment; FemSperm®, a CLIA waived sperm preparation and analysis product line; and FemVue®, a companion diagnostic for fallopian tube assessment. Published clinical trial data demonstrate that FemaSeed achieved more than double the pregnancy rates of traditional IUI, with a comparable safety profile and high patient and practitioner satisfaction.1

FemBloc® permanent birth control is the first and only non-surgical, in-office alternative to centuries-old surgical sterilization that received full regulatory approval in Europe in June 2025, the UK in August 2025, and New Zealand in September 2025. Commercialization of this highly cost-effective, convenient and significantly safer approach will be completed through strategic partnerships in select European countries. Alongside FemBloc, the FemChec®, diagnostic product provides an ultrasound-based test to confirm procedural success. Published data from initial clinical trials demonstrated compelling effectiveness, five-year safety, and high patient and practitioner satisfaction.2 For U.S. FDA approval, enrollment in the FINALE pivotal trial (NCT05977751) is on-going.

Learn more at www.femasys.com, or follow us on X, Facebook and LinkedIn.

References
1Liu, J. H., Glassner, M., Gracia, C. R., Johnstone, E. B., Schnell, V. L., Thomas, M. A., L. Morrison, Lee-Sepsick, K. (2024). FemaSeed Directional Intratubal Artificial Insemination for Couples with Male-Factor or Unexplained Infertility Associated with Low Male Sperm Count. J Gynecol Reprod Med, 8(2), 01-12. doi: 10.33140/JGRM.08.02.08.

2Liu, J. H., Blumenthal, P. D., Castaño, P. M., Chudnoff, S. C., Gawron, L. M., Johnstone, E. B., Lee-Sepsick, K. (2025). FemBloc Non-Surgical Permanent Contraception for Occlusion of the Fallopian Tubes. J Gynecol Reprod Med, 9(1), 01-12. doi: 10.33140/JGRM.09.01.05.

Forward-Looking Statements 
This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to obtain regulatory approvals for our FemBloc product candidate; develop and advance our current FemBloc product candidate and successfully enroll and complete the clinical trial; the ability of our clinical trial to demonstrate safety and effectiveness of our product candidate and other positive results; estimates regarding the total addressable market for our products and product candidate; our ability to commercialize our products and product candidate, our ability to establish, maintain, grow or increase sales and revenues, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.

Contacts: 
David Gutierrez, Dresner Corporate Services, (312) 780-7204, dgutierrez@dresnerco.com
Nathan Abler, Dresner Corporate Services, (714) 742-4180, nabler@dresnerco.com

Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting

Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting




Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting

Selected for oral presentation at Clinical Trials Mini Symposium

SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced the presentation of data from the Phase 1 trial of PLN-101095 at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place in San Diego, California from April 17-22, 2026.

The abstract was selected for oral presentation as part of the Clinical Trials Mini Symposium.

Oral Presentation

Title: First-in-human phase I study of PLN-101095, a first-in-class dual αvβ8/αvβ1integrin inhibitor, as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors refractory to immune checkpoint inhibitors (ICI)

Presenter: Timothy A. Yap, M.D., Ph.D., University of Texas, M.D. Anderson Cancer Center
Session: CTMS01: Updates in Anticancer Immunotherapies
Date: Saturday, April 18, 2026
Presentation Time: 10:21 a.m. – 10:31 a.m. Pacific Time
Location: Ballroom 6A – Upper Level – San Diego Convention Center

Oncology Program

PLN-101095 is an oral, small molecule, dual selective inhibitor of αvβ8 and αvβ1 integrins designed to overcome checkpoint resistance by blocking TGF-β activation in the tumor microenvironment. Pliant is currently conducting a Phase 1a/1b open-label, dose-escalation and indication expansion trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of PLN-101095, as monotherapy and in combination with pembrolizumab, in patients with immune checkpoint inhibitor (ICI)-refractory advanced or metastatic solid tumors.

About Pliant Therapeutics, Inc.

Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of integrin-based therapeutics. The Company’s lead program is PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. Pliant’s early-stage platform includes preclinical research focused on tissue-specific delivery and internalization of drug payloads utilizing integrin receptor-binding molecules. For additional information, please visit: www.PliantRx.com. Follow us on social media X, LinkedIn and Facebook.

Investor and Media Contact:

Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com

Red Light Holland Engages Kala Bio’s Researgency.AI Platform to Support Clinical Development of Filament’s Patented PEX010 Botanical Psilocybin Drug Candidate

Red Light Holland Engages Kala Bio’s Researgency.AI Platform to Support Clinical Development of Filament’s Patented PEX010 Botanical Psilocybin Drug Candidate




Red Light Holland Engages Kala Bio’s Researgency.AI Platform to Support Clinical Development of Filament’s Patented PEX010 Botanical Psilocybin Drug Candidate

  • AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio’s purpose-built agentic AI platform for the biotechnology industry

TORONTO and ARLINGTON, Mass., March 18, 2026 (GLOBE NEWSWIRE) — Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) (“Red Light” or the “Company”) and Kala Bio, Inc. (NASDAQ: KALA) (“Kala Bio”) today announced that Red Light has engaged Kala Bio’s with its Researgency.ai agentic artificial intelligence platform under world wide license from Younet to support the clinical development strategy for PEX010, the patented botanical psilocybin drug candidate originated by Filament Health Corp. (“Filament”). The engagement will deploy Kala Bio’s purpose-built AI research agents to assist in clinical planning, protocol optimization and scenario modeling as Red Light advances PEX010 through its regulated drug development program.

Red Light recently announced a definitive arrangement agreement to acquire Filament’s business, including its portfolio of 76 issued patents across 15 patent families, representing one of the largest intellectual property portfolios in botanical psilocybin drug development, as well as its lead drug candidate, PEX010.

Strategic Rationale

The engagement of the Kala’s Researgency.ai platform represents a key element of Red Light’s strategy to integrate advanced AI-driven research capabilities as it expands its regulated psychedelic drug development platform. By deploying custom purpose-built AI agents trained by Younet engineers in collaboration with Kala and under private cloud LLM infrastructure (supplied by Kala), Red Light intends to accelerate and enhance research planning, scenario simulation, and protocol optimization processes associated with advancing PEX010 through its clinical development program.

PEX010 is Filament’s patented botanical psilocybin drug candidate and is currently supplied to more than 70 clinical research sites worldwide, making it one of the most widely studied botanical psilocybin drug candidates in regulated clinical research. PEX010 is being studied across multiple indications, including alcohol use disorder, methamphetamine use disorder, treatment-resistant depression, cancer-related anxiety and depression, and cannabis use disorder, at leading research institutions including Johns Hopkins University and Dana-Farber Cancer Institute, among others. These indications represent areas of growing clinical and commercial momentum, with programs from Compass Pathways and AtaiBeckley also advancing psilocybin and psychedelic candidates toward late-stage regulatory milestones, and Johnson & Johnson’s Spravato continuing to demonstrate strong commercial traction in treatment-resistant depression.

The drug candidate has received both Health Canada and U.S. Food and Drug Administration authorization for clinical trials and has demonstrated positive Phase 2 clinical data in alcohol use disorder.

Researgency.ai is an agentic AI platform developed by Younet.ai with exclusive worldwide distribution/development license owned by Kala Bio, designed to deploy secure, on-premises AI agents purpose-built for biotechnology and pharmaceutical R&D workflows. The platform enables autonomous research loops capable of generating, simulating, and optimizing study scenarios at scale — compressing timelines and expanding the number of viable options considered before execution. The approach mirrors a broader industry shift toward purpose-built AI infrastructure for drug development, an area where NVIDIA and Eli Lilly have also committed significant resources through dedicated computing partnerships and in-house platforms.

Management Commentary

“As we move to integrate Filament’s exceptional clinical assets and intellectual property, engaging Kala Bio’s Researgency.ai platform is a natural next step in building a best-in-class psychedelic drug development operation,” said Todd Shapiro, Chief Executive Officer and Director of Red Light Holland. “PEX010 is already one of the most widely studied botanical psilocybin drug candidates in the world. By applying autonomous AI-driven research capabilities to our clinical development planning, we believe we can accelerate timelines, strengthen study designs, and make smarter, faster decisions across PEX010’s extensive clinical program.”

“Filament’s focus from the beginning has been to build a strong scientific and intellectual property foundation for botanical psilocybin drug development,” said Ben Lightburn, Chief Executive Officer of Filament Health Corp. “With PEX010 already supporting a growing body of global clinical research, the application of advanced analytical tools such as Kala Bio’s Researgency.ai platform has the potential to further strengthen how clinical development strategies are evaluated as the program continues to evolve.”

“Red Light’s decision to deploy Researgency.ai in support of PEX010 underscores exactly the kind of high-value, data-intensive challenge our platform was built to address,” said Avi Minkowitz, Chief Executive Officer of Kala Bio. “Psychedelic drug development is a complex, rapidly evolving field where the ability to quickly simulate and evaluate clinical scenarios can make a meaningful difference. We are excited to work with the Red Light team as they advance one of the leading botanical psilocybin programs in the world.”

About Researgency.ai

Researgency.ai is an agentic AI platform under worldwide distribution/development license by Kala Bio Inc. (NASDAQ: KALA) launched by Younet.ai, designed to bring autonomous research-agent workflows to biotechnology R&D planning. The platform deploys purpose-built AI agents that can simulate scenarios, optimize protocols, and support evidence-driven decisions in a secure, on-premises environment built for pharmaceutical-grade compliance. For more information, visit www.Researgency.ai.

About PEX010

PEX010 is a patented botanical psilocybin drug candidate developed by Filament Health Corp. PEX010 is formulated as a capsule for oral administration and is protected by Filament’s portfolio of 76 issued patents across 15 patent families covering natural psilocybin extraction, purification, standardization, stabilization, and alternative delivery formulations. PEX010 is currently supplied to more than 70 clinical research sites worldwide and is being studied in multiple Health Canada and FDA-authorized clinical trials across a range of mental health indications.

About Red Light Holland

Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) is a Toronto-based company advancing a focused strategy within the legal psychedelic sector, centered on voluntary data collection and R&D initiatives designed to expand naturally occurring drug development and understanding of psilocybin use and consumer experiences. The Company operates commercial activities across Europe and North America, including psilocybin truffle sales in the Netherlands’ legal market and mushroom home grow kits offered through B2B and DTC channels, in compliance with applicable laws. Red Light has entered into a definitive arrangement agreement to acquire Filament Health Corp., which is expected to expand the Company’s drug development platform with GMP manufacturing capabilities, comprehensive Health Canada licensing, FDA-authorized clinical programs, and a portfolio of 76 issued patents. For more information, visit www.RedLight.co.

About Filament Health

Filament Health is a clinical-stage natural psychedelic drug development company. Filament believes that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and its mission is to see them in the hands of everyone who needs them as soon as possible. Filament’s platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. Filament is paving the way with the first-ever natural psychedelic drug candidates. 

About Kala Bio, Inc.

Kala Bio, Inc. (NASDAQ: KALA) is a clinical-stage biopharmaceutical company building a dedicated, on-premises AI infrastructure platform for the biotechnology industry. The Company’s dual strategy combines a proprietary biologics pipeline, including its mesenchymal stem cell secretome (MSC-S) platform and FDA Orphan Drug and Fast Track designated product candidates, with a scalable AI platform-as-a-service business designed to deploy secure, purpose-built AI systems directly within biotech and pharmaceutical client environments. Through its exclusive worldwide license for the Researgency AI research platform from Younet, Kala intends to serve as the dedicated AI infrastructure partner for the biotechnology industry. For more information, visit www.kalarx.com.

For additional information on Red Light Holland:

Todd Shapiro 
Chief Executive Officer & Director 
Tel: 647-204-7129 
Email: todd@redlight.co 
Website: www.RedLight.co

For additional information on Filament:

Benjamin Lightburn
Chief Executive Officer & Director 
Email: ben@filament.health
Website: www.filament.health

For additional information on Kala Bio, Inc.:

Kala Bio, Inc.
Avi Minkowitz
Chief Executive Officer
Email: am@kalarx.com
Website: www.kalarx.com
www.Researgency.ai

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable Canadian and United States securities legislation, including statements regarding the expected benefits and applications of the Researgency.ai platform in connection with PEX010 and Red Light’s drug development programs; the anticipated impact of AI-driven research tools on clinical development timelines and decision-making; the expected completion of Red Light’s acquisition of Filament; and the future development and commercialization of PEX010. Forward-looking statements are based on management’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including, among others: the ability to develop, deploy, and integrate new AI technologies; the performance and reliability of AI models and simulations; data availability and quality; cybersecurity and privacy considerations; the regulatory environment for psychedelic substances and AI-driven tools in Canada, the United States, and internationally; the ability to complete the acquisition of Filament on the anticipated terms and timeline; the ability to realize the anticipated benefits of the Filament transaction; the ability to retain key personnel; risks inherent in clinical drug development; and other risks described in Red Light’s and Kala Bio’s respective public filings. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Neither Red Light nor Kala Bio undertakes any obligation to update any forward-looking statements to reflect events or circumstances after the date of this release, except as required by law.

VIVUS Confirms QSIVA® Price Reduction Is Now Effective Across Nordics and Poland

VIVUS Confirms QSIVA® Price Reduction Is Now Effective Across Nordics and Poland




VIVUS Confirms QSIVA® Price Reduction Is Now Effective Across Nordics and Poland

— The lowered pricing structure is now available for 101.82 EUR per bottle at pharmacies throughout Finland

AMSTERDAM, March 18, 2026 (GLOBE NEWSWIRE) — VIVUS BV, a subsidiary of VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious medical conditions and life-limiting diseases, today announced the new price reduction of QSIVA® hard modified-release capsules phentermine/topiramate, is now in effect in Finland. The updated pricing reflects an average cost of 3.39 EUR per day, or considering the completer results on the top dose from the pivotal clinical trials, it is approximately 98 EUR per kilogram of weight loss. An individual’s results may vary.

“The price reduction of QSIVA is genuinely welcome. Too often, I see patients forced to stop a medication that is working for them simply because the cost is too high. Lowering the price is a step toward more equitable access to effective obesity care—regardless of income. Obesity is a chronic disease and, for many people, requires long-term treatment and follow-up. Medication can be an important and effective part of care, alongside lifestyle support. Just as importantly, patients benefit from structured, multidisciplinary follow-up so treatment can be individualized—choosing the right option, adjusting the dose when needed, and supporting sustainable health behaviours in the long run,” said Emilia Huvinen, Naistentautien ja synnytysten erikoislääkäri, LT.

According to the 2025 World Obesity Atlas, 22% of Finnish adults live with obesity, and 57% of adults have a high body mass index (BMI). Excess body weight is associated with an increased risk of serious health conditions, including cardiovascular disease, stroke, and diabetes, which are among the leading causes of mortality. Effective treatment options such as QSIVA can support patients in achieving and maintaining clinically meaningful weight loss, helping to improve long-term health outcomes and overall well-being.

“Obesity remains a significant public health challenge in Finland, affecting millions of people and increasing the risk of serious, chronic diseases,” said John Amos, Chief Executive Officer at VIVUS LLC. “With this price reduction now in effect, we aim to improve access to QSIVA and support healthcare professionals and patients in addressing obesity through evidence-based treatment options.”

In the Phase III CONQUER trial, a 56-week clinical study, QSIVA demonstrated that subjects assigned to treatment achieved 7.8 – 10.9 percent weight reduction (ITT analysis) and 7.6 – 10.9 cm reduction of waist circumference after 56 weeks of treatment. Subjects who were treated with QSIVA for the full 56-week study period (completer on drug analysis) achieved 9.6 – 14.4 percent weight reduction and 9.4 – 13.6cm reduction of waist circumference after completion of treatment. These clinical trials also demonstrated that phentermine/topiramate in combination with a weight-loss diet and exercise program resulted in statistically significant and clinically important reductions vs. placebo in weight and waist circumference, coupled with improvements in important risk markers indicative of weight-related comorbidities, such as systolic and diastolic BP, triglycerides, fasting glucose and progression towards type 2 diabetes. QSIVA is available in the mid and top dose strengths evaluated in the Phase III CONQUER trial along with 2 other dose strengths. Dose selection should be individualized and determined by the treating physician based on patient characteristics, treatment response, and tolerability, in accordance with the approved prescribing information.

About VIVUS
VIVUS is a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs. For more information about the Company, please visit https://vivus.com/.

About QSIVA
QSIVA (the European brand name for QSYMIA) is approved in Sweden, Denmark, Finland, Iceland, and Poland. QSIVA is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol. The effect of QSIVA on reducing cardiovascular morbidity and mortality has not been established. The safety and effectiveness of QSIVA in combination with other products intended for weight loss, including prescription and over-the-counter drugs and herbal preparations, have not been established. For more information on QSIVA, please visit QSIVA.eu. The website is accessible for healthcare professionals only through registration.

Important Safety Information for QSIVA

QSIVA® hard modified-release capsules phentermine/topiramate is contraindicated in pregnancy and in women of childbearing potential not using highly effective contraception; in patients with glaucoma; in hyperthyroidism; in patients receiving treatment or within 14 days following treatment with monoamine oxidase inhibitors (MAOIs); in patients with hypersensitivity to sympathomimetic amines, to the active substances, or to any of the excipients in QSIVA.

QSIVA can cause foetal harm. It is recommended that patients who can become pregnant obtain a negative pregnancy test result before starting QSIVA treatment, perform monthly pregnancy testing, and use highly effective contraception while taking QSIVA. If a patient becomes pregnant while taking QSIVA, treatment should be discontinued immediately, and the patient should consult promptly with their doctor. The most common adverse reactions in adults are paraesthesia, dizziness, an altered or impaired sense of taste, insomnia, depression, constipation, and dry mouth.

Forward-Looking Statements

Important Information and Cautionary Note Regarding Forward-Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and/or covered by the “Bespeaks Caution” doctrine applied by the courts under the antifraud provisions of the federal securities laws, and other applicable provisions of the federal securities laws. Such forward-looking statements are based on current expectations, management’s beliefs, and certain assumptions made by the Company’s management. These statements may be identified by the use of forward-looking words such as “will,” “shall,” “may,” “believe,” “expect,” “forecast,” “intend,” “anticipate,” “predict,” “should,” “plan,” “likely,” “opportunity,” “estimated,” and “potential,” and/or the negative use of these words or other similar words. All forward-looking statements included in this document are based on the Company’s current expectations, and the Company assumes no obligation to update any such forward-looking statements except to the extent otherwise required by law.

Forward-looking information about QSIVA, including statements regarding its clinical efficacy, safety profile, the anticipated impact of the price reduction on patient access and commercial performance, and its role in long-term obesity management, involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied in this press release.

Risks related to QSIVA include the potential benefits of the price reduction on patient access and uptake, the impact of revised pricing strategies on revenue and commercial performance, the continued success of pharmacy partnerships across the Nordics and Poland, competitive developments in the weight management market including injectable medications, and whether QSIVA will continue to be commercially successful in approved markets.

General risks include the ability to successfully manage commercial programs across multiple international markets; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of QSIVA; supply chain challenges; and competitive developments in the obesity and weight management therapeutic area.

The above factors, risks, and uncertainties are difficult to predict, contain uncertainties that may materially affect actual results, and may be beyond the Company’s control. New factors, risks, and uncertainties emerge from time to time, and it is not possible for management to predict all such factors, risks, and uncertainties. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore any of these statements may prove to be inaccurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation or warranty by the Company or any other person that the Company’s objectives and plans will be achieved. These forward-looking statements speak only as of the date such statements were made or any earlier date indicated, and the Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, changes in underlying assumptions, or otherwise, unless otherwise required by law. This announcement is made in accordance with applicable securities regulations including the EU Market Abuse Regulation.

Contacts

VIVUS BV
T: +31 20 262 0959

Media – FINN Partners
Julian Tyndale-Biscoe
julian.tyndale-biscoe@finnpartners.com
T: +44 20 7046 8280

Niagen Bioscience to Present at the 38th Annual ROTH Conference

Niagen Bioscience to Present at the 38th Annual ROTH Conference




Niagen Bioscience to Present at the 38th Annual ROTH Conference

LOS ANGELES–(BUSINESS WIRE)–$NAGE #Biotech—Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will participate at the 38th Annual ROTH Conference, taking place at The Ritz-Carlton Laguna Niguel in Dana Point, California, from March 22 to 24, 2026.


Niagen Bioscience CEO, Rob Fried, will participate in the Technologies Advancing Healthy Aging Panel on Monday, March 23, at 2:00 PM PT (5:00 PM ET). The panel will be livestreamed and available at www.event.summitcast.com. Additionally, Niagen Bioscience’s CEO, Rob Fried, and CFO, Ozan Pamir, will attend one-on-one meetings with institutional investors in person throughout the day.

This year’s event will consist of one-on-one and small-group meetings, analyst-selected fireside chats, industry keynotes, and panels, with executive management from hundreds of private and public companies across a variety of growth sectors in attendance.

Investors interested in arranging one-on-one meetings should contact their ROTH representative. To learn more and submit a registration request, click here.

The Technologies Advancing Healthy Aging Panel will be livestreamed and available at www.event.summitcast.com.

For additional information on Niagen Bioscience, visit www.niagenbioscience.com.

About Niagen Bioscience:

Niagen Bioscience, Inc. (NASDAQ: NAGE) is the global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions.

The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality.

Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There’s a better way to age.

At the heart of its clinically proven product portfolio is Niagen® (patented nicotinamide riboside, or NR), the most efficient, well-researched, and high-quality NAD+ booster available. Niagen powers the Company’s consumer supplement, Tru Niagen®, the number one NAD+ boosting oral supplement in the United States† (available at www.truniagen.com), and Niagen Plus™, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products (www.niagenplus.com). Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription.

Niagen Bioscience’s robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at www.niagenbioscience.com, where copies of press releases, news, and financial information are regularly published.

†Based on revenue per largest U.S. e-commerce marketplace (Jan. 2025 – Dec. 2025)

About ROTH:

ROTH is a relationship-driven investment bank focused on serving growth companies and their investors. Their full service platform provides capital raising, high impact equity research, macroeconomics, sales and trading, technical insights, derivatives strategies, M&A advisory, and corporate access. Headquartered in Newport Beach, California, ROTH is a privately-held, employee owned organization and maintains offices throughout the U.S. For more information, please visit www.roth.com.

Contacts

Niagen Bioscience Media Contact:
Kendall Knysch, Senior Director of Media Relations & Partnerships

310.405.5227

kendall.knysch@niagenbio.com

Niagen Bioscience Investor Relations Contact:
Valter Pinto, Managing Director

KCSA Strategic Communications

212.896.1254

Niagen@kcsa.com

Crossbow Therapeutics Raises $77 Million in Series B Financing to Advance Development of TCR-mimetic Antibody Therapies to Treat Cancer

Crossbow Therapeutics Raises $77 Million in Series B Financing to Advance Development of TCR-mimetic Antibody Therapies to Treat Cancer




Crossbow Therapeutics Raises $77 Million in Series B Financing to Advance Development of TCR-mimetic Antibody Therapies to Treat Cancer

Financing co-led by Taiho Ventures and Arkin Bio Capital with significant participation from other new and existing investors

Investment enables continued clinical development of T-Bolt™ therapies, including completion of CBX-250 Phase 1 trial and initiation of CBX-663 clinical trial

Preclinical and translational updates on both programs to be presented at the American Association for Cancer Research (AACR) 2026 Annual Meeting

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Crossbow Therapeutics, Inc., a biotechnology company developing a novel class of potent and precise antibody therapies to treat a broad range of cancers, today announced it has raised $77 million in a Series B financing that will support the completion of the CROSSCHECK-001 Phase 1 clinical trial of the company’s lead program, CBX-250, and accelerate development of additional T-Bolt™ immunotherapies designed to extend the reach of antibody therapy across a broad range of cancers.


This Series B financing was co-led by Taiho Ventures and Arkin Bio Capital, with participation from new investors Sixty Degree Capital, Hamilton Square Partners Management LP, LifeLink Ventures, Libbs Ventures, and Blood Cancer United’s Therapy Acceleration Program® (TAP), as well as existing investors MPM BioImpact, Pfizer Ventures, BVF Partners, Polaris Partners, Eli Lilly and Company, and Mirae Asset Venture Investment. As part of the financing, Sakae Asanuma, President & CEO of Taiho Ventures, and Pini Orbach, Managing Partner of Arkin Bio Capital, have joined Crossbow’s Board of Directors.

Crossbow is developing a broad portfolio of novel T-cell engager (TCE) therapies that potently target peptide human leukocyte antigen (pHLA) on cancer cells, using antibodies that mimic T-cell receptors (TCR-mimetics). These investigational products, known as T-BoltTM molecules, can be adapted to address a broad range of malignancies, potentially targeting the entire universe of cancer proteins.

“This financing not only strengthens our ability to advance CBX-250 through clinical development but also accelerates our mission to bring next-generation TCR-mimetic immunotherapies to patients who urgently need new options,” said Briggs Morrison, M.D., Chief Executive Officer of Crossbow Therapeutics. “We greatly appreciate our investors for sharing our conviction in the transformative potential of our T-BoltTM platform. We look forward to efficiently expanding our pipeline to address cancers that remain beyond the reach of today’s therapies.”

The Series B financing will allow Crossbow to complete a Phase 1 clinical trial of CBX-250, Crossbow’s first-in-class TCE therapy, which targets a pHLA specific to myeloid cancer cells. The ongoing Phase 1 study (CROSSCHECK-001) is evaluating CBX-250 in patients with relapsed and refractory myeloid malignancies including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), myelodysplastic syndromes (MDS), and chronic myelomonocytic leukemia (CMML). Initial clinical data from the CROSSCHECK-001 trial are expected around the end of 2026.

The financing will also enable submission of an Investigational New Drug (IND) application and initiation of a Phase 1 trial of CBX-663, a first-in-class TCE targeting a telomerase reverse transcriptase (TERT)-derived pHLA for the treatment of multiple hematologic and solid tumors. The initiation of the Phase 1 study evaluating CBX-663 is projected for Q3 2026.

Crossbow researchers will present preclinical findings for CBX-250 in myeloid malignancies as well as the characterization of CBX-663 in models of solid tumors at the upcoming American Association for Cancer Research (AACR) 2026 Annual Meeting in San Diego, Calif., which takes place April 17-22, 2026.

“Crossbow’s arsenal of T-cell engagers represents a differentiated and promising approach to anti-cancer immunotherapy by addressing the wide variety of intra-cellular targets and broadens the potentials of TCE modality,” commented Sakae Asanuma, President & CEO of Taiho Ventures and Crossbow board member. “The company’s experienced team and versatile platform position it to overcome the limitations of current treatments and deliver impact for patients in need. We are excited to continue supporting Crossbow as it advances its lead programs into the clinic.”

About Crossbow Therapeutics, Inc.

Crossbow Therapeutics, Inc., is a biotechnology company determined to improve the lives of people with cancer by unlocking the therapeutic potential of T-cell receptor (TCR)-mimetic antibodies. The company’s T-BoltTM therapies are next-generation, easily assembled immunotherapies directed with high precision at previously unreachable cancer cell targets. Crossbow’s efficient and selective approach is designed to target the entire universe of cancer proteins, dramatically expanding the potential of antibody therapy to address many types of cancer.

AACR 2026 Annual Meeting presentation details:

CBX-250 (Oral Presentation)

  • Title: Preclinical evaluation and safety of CBX-250 in acute myeloid leukemia: A bispecific T cell engager targeting Cathepsin-G peptide/HLA Complex (abstract #4056)
  • Presenting Author: Jennifer Helble, PhD
  • Session Title: Advances in Therapeutic Antibodies
  • Presentation Date/Time/Location: Monday Apr. 20, 2026, 3:50PM-4:05PM PDT, San Diego Convention Center – Ballroom 20 CD (Upper Level)
  • Full text of the abstract is available here.

CBX-663 (Poster Presentation)

  • Title: CBX-663, a first-in-class TCR-mimetic T-Cell Engager targeting the TERT peptide-HLA complex, mediates potent cytotoxicity in vitro and tumor inhibition in vivo in preclinical models of solid malignancies (abstract #1635)
  • Session Title: T Cell Engagers 1
  • Session Date/Time/Location: Monday Apr. 20, 2026, 9:00AM-12:00PM PDT, San Diego Convention Center, Poster Section 10, Poster Board Number 27
  • Full text of the abstract is available here.

For additional details on the CROSSCHECK-001 Phase 1 trial, visit https://clinicaltrials.gov/study/NCT06994676.

For more information about Crossbow Therapeutics, visit www.crossbowtx.com.

About Taiho Ventures, LLC

Taiho Ventures, LLC is a strategic corporate venture capital arm of Taiho Pharmaceutical Co., Ltd., a Japanese specialty pharma focusing on oncology, allergy and immunology. Taiho Ventures is looking at early-stage preclinical oncology companies as well as platform technology companies for our core therapeutic areas. Taiho Ventures will review a wide variety of modalities, including both biologics and small molecules. The company will also consider option-type investments and spin-outs, in addition to the pure equity investments. For more information about Taiho Ventures, please visit https://www.taihoventures.com/.

About Arkin Bio Capital

Arkin Bio Capital is a global biotech fund dedicated to supporting clinical stage biotech companies approaching proof of concept in patients. Arkin Bio Capital leads investments alongside top global partners, driving robust growth and impactful advancements. Our team has a strong background in biopharmaceuticals, drug development, business development, and management, with a proven track record. Arkin Bio Capital seeks to invest in companies with innovative therapeutic candidates and experienced managements and is committed to nurturing promising opportunities and ensuring the success of each investment. For more information about Arkin Bio Capital, please visit https://arkin-capital.com/bio/.

Contacts

Investor Contact:
Crossbow Therapeutics, Inc.

Geraldine Paulus, Co-Founder, Senior Vice President and Head of Corporate Development and Business Operations

Geraldine.Paulus@crossbowtx.com

Media Contact:
SmithSolve

Alex Van Rees

Alex.VanRees@smithsolve.com

Darwin AG launches commercialization of Multi-Cancer Check — a blood test for early detection of 13 types of cancer

Darwin AG

/ Key word(s): Alliance/Product Launch

Darwin AG launches commercialization of Multi-Cancer Check — a blood test for early detection of 13 types of cancer

18.03.2026 / 10:00 CET/CEST

The issuer is solely responsible for the content of this announcement.


Corporate News

Darwin AG launches commercialization of Multi-Cancer Check — a blood test for early detection of 13 types of cancer

Munich, March 18, 2026 – Darwin AG (ISIN DE000A3C35W0) today announced the launch of its innovative Multi-Cancer Check blood test for early cancer detection. The test was developed in collaboration with Wholomics GmbH and will initially be sold primarily through the Company’s 70% subsidiary NovoMedic GmbH. The Multi-Cancer Check is based on innovative liquid biopsy technology and multi-omics analysis with its performance data setting new standards in preventive oncology.

The Multi-Cancer Check is a non-invasive and highly specific blood test for cancer diagnosis that can detect molecular signals from several types of tumors simultaneously. Unlike many currently available liquid biopsy tests that focus on individual types of cancer, the Multi-Cancer Check allows for broad pre-screening for a total of 13 common types of cancer, including colon, uterus, ovarian, lung, and bladder cancer, thus enabling the detection of a particularly wide range of solid tumors.

In a validation study, the Multi-Cancer Check demonstrated very high sensitivity, especially in early stages of cancer, combined with excellent specificity. The test thus sets a new standard in non-invasive, blood-based early cancer detection. A total of 862 samples, including 440 confirmed cancer cases, were analyzed. The test achieved a sensitivity of 80.7% with a specificity of 99.1% and showed a sensitivity of 82.5% even in stage I. The Multi-Cancer Check produced only three false positive results.

“We are very pleased to introduce the Multi-Cancer Check, a first-class test for early cancer detection, to the market,” says CEO Dr. Daniel Wallerstorfer. “Cancer survival rates depend largely on how early the disease is detected. Our test was developed precisely for this purpose, to identify cancer with high accuracy even before symptoms appear. We are convinced that the Multi-Cancer Check, with its combination of high sensitivity in early stages and very high specificity, as well as its ability to detect different types of cancer, can make a decisive contribution to preventive medicine.”

The Multi-Cancer Check is based on a sophisticated multi-omics analysis in which more than 150 metabolites, lipoproteins, and other biomarkers are examined using nuclear magnetic resonance. The molecular signatures are evaluated using an artificial intelligence (AI) algorithm developed by cooperation partner Wholomics GmbH. The test detects common molecular signals from various solid tumors without clearly localizing the organ of origin. Positive test results should therefore be confirmed by diagnostic imaging procedures.

The global market for liquid biopsies, i.e., non-invasive biopsies or blood tests for early cancer detection and therapy monitoring, is currently estimated at around USD 7 billion and, according to market studies, is expected to grow to over USD 22 billion by 2034, corresponding to an annual growth rate of around 14%.[1] Growth is being driven in particular by the increasing use of minimally invasive or non-invasive diagnostic procedures such as liquid biopsies, which offer significant advantages over traditional tissue biopsies and are therefore increasingly being used in cancer detection and treatment. Compared to traditional tissue biopsies, non-invasive liquid biopsies offer the advantage of fewer complications, ease of repetition, and the ability to map tumor changes in real time. They can provide important molecular information about a tumor, especially in cases of hard-to-reach cancers, making the different biological characteristics of tumors more visible and enabling physicians to make more targeted, personalized treatment decisions.

 

About Darwin AG

The “Darwin Group” (i.e. Darwin AG including its subsidiaries), headquartered in Munich (Germany), is a European healthcare company, particularly active in the field of human genetics and the development of personalized products based on genetic analysis. The genetic analyses conducted in the company’s own laboratory are used in the diagnosis, treatment, and prevention of diseases, as well as in the production of individually tailored nutritional supplements and cosmetics. Darwin also acts as a partner to physicians, therapists, pharmacists, nutritionists, and fitness trainers, helping to ensure treatment or support that is as optimal as possible for the patient’s or client’s needs by analyzing their respective genetic predispositions. In addition, Darwin holds investments in innovative companies in the biotech, healthcare, and life sciences sectors. More information: https://darwin-biotech.com/

[1] Precedence Research, Liquid Biopsy Market Size, Share and Trends 2025 to 2034

Contact:

Darwin AG
Brienner Str. 7
80333 Munich
Phone: +49 89 – 20 500 450
investor.relations@darwin-biotech.com
Media contact
MC Services AG
Katja Arnold, Pamela Keck
Phone.: +49 89 – 210 228-0
darwin@mc-services.eu
 
 


18.03.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


2292778  18.03.2026 CET/CEST